Renal Cell Carcinoma

Title	Average Rating
Systems biology: a therapeutic target for tumor therapy.	86.67%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m	80.00%
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.	80.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli	70.00%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).	70.00%
Role of everolimus in the treatment of renal cell carcinoma.	50.00%
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar...	30.00%

Languages